Acta Scientific Pharmacology (ASPC)

Review Article Volume 1 Issue 1

Evidence Based Practice towards Pharmacological Management of Persistent Pulmonary Hypertension of Newborn in Neonatal Intensive Care Unit

Virender Verma1*, Priya Soni2, Sanjiv Nanda3, Anjani Kumar1, Vivek Nandan4, Shanu Prabhakar4 and Joshi Anand K5

1Consultant Pediatrician and Neonatal Intensivist, Ruban Hospital, Patna, India
2Consultant Emergency Physician, Ruban Hospital, Patna, India
3Senior Prof Pediatrics, PGIMS, Rohtak, India
4Senior Residents Pediatrics, Ruban Hospital, Patna, India
5Senior Consultant Pediatrics and Neonatology, The Mission Hospital, Durgapur, India

*Corresponding Author: Virender Verma, Consultant Pediatrics and Neonatology, Lead: Pediatric Intensive Care, Ruban Hospital, Patna, India.

Received: December 23, 2019; Published: December 31, 2019

×

  Persistent pulmonary hypertension of newborn (PPHN) is a common problem encountered in neonatal intensive care units. The problem arise because of failure of smooth transition from fetal circulation to post-natal circulation after birth. This causes hypoxemia due to high resistance in pulmonary vasculature causing impediment into normal pulmonary blood flow apparently causing right – to – left shunt.
  The problem is more commonly associated with fullterm neonates and there are a number of therapies available to manage the problem. This article discusses the evidence based approach towards the pharmacological management of persistent pulmonary hypertension of newborn.

Keywords:Persistent Pulmonary Hypertension of Newborn; PPHN; Pharmacological Management; Neonate; NICU; Newborn; Hypoxia; Neonatal Ventilator Dependency; iNO; Inhaled Nitric Oxide; Pulmonary Hypertension

×

References

  1. BENDAPUDI P., et al. “Diagnosis and management of persistent pulmonary hypertension of the newborn”. Paediatric Respiratory Reviews 16 (2015): 157-61.
  2. OSTREA EM., et al. “Persistent pulmonary hypertension of the newborn: pathogenesis, etiology, and management”. Paediatr Drugs 8 (2006): 179-188.
  3. FULORIA M and ASCHNER JL. “Persistent pulmonary hypertension of the newborn”. Seminars in Fetal and Neonatal Medicine 22 (2017): 220-226.
  4. ALAPATI D., et al. “Management of Supplemental Oxygen for Infants with Persistent Pulmonary Hypertension of Newborn: A Survey”. American Journal of Perinatology 34 (2017): 276-282.
  5. OKA M., et al. “Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension”. British Journal of Pharmacology 155 (2018): 444-454. 
  6. SHARMA V., et al. “Persistent pulmonary hypertension of the newborn”. Maternal Health, Neonatology and Perinatology 1 (2015): 14.
  7. DANI C., et al. “Nitric oxide for the treatment of preterm infants with severe RDS and pulmonary hypertension”. Pediatric Pulmonology 52 (2017): 1461-1468.
  8. KONDURI GG and KIM UO. “Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn”. Pediatric Clinics of North America 56 (2009): 579-600.
  9. OLIVEIRA CA., et al. “Inhaled nitric oxide in the management of persistent pulmonary hypertension of the newborn: a meta-analysis”. Revista do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo 55 (2000): 145-154.
  10. GADZINOWSKI J., et al. “Treatment of MAS with PPHN using combined therapy: SLL, bolus surfactant and iNO”. Journal of Perinatology 28 (2008): S56-66.
  11. MCHONEY M. “Congenital diaphragmatic hernia, management in the newborn”. Pediatric Surgery International 31 (2015): 1005-1013.
  12. MATHEW B and LAKSHMINRUSIMHA S. “Persistent Pulmonary Hypertension in the Newborn”. Children (Basel) 4 (2017).
  13. DA COSTA DE., et al. “Steroids in full term infants with respiratory failure and pulmonary hypertension due to meconium aspiration syndrome”. European Journal of Pediatrics 160 (2001): 150-153.
  14. LAI MY., et al. “Beyond the inhaled nitric oxide in persistent pulmonary hypertension of the newborn”. Pediatric Neonatology 59 (2018): 15-23.
  15. KELLY LE., et al. “Sildenafil for pulmonary hypertension in neonates”. Cochrane Database System Review 8 (2017): CD005494.
  16. ABMAN SH., et al. “Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension”. American Journal of Respiratory and Critical Care Medicine 187 (2013): 572-575.
  17. PEREZ KM and LAUGHON M. “Sildenafil in Term and Premature Infants: A Systematic Review”. Clinical Therapy 37 (2015): 2598-2607.e1.
  18. BASSLER D., et al. “Milrinone for persistent pulmonary hypertension of the newborn”. Cochrane Database System Review (2010).
  19. MOHAMED WA and ISMAIL M. “A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn”. Journal of Perinatology 32 (2012) 608-613.
  20. MANEENIL G., et al. “Effect of bosentan therapy in persistent pulmonary hypertension of the newborn”. Pediatric and Neonatology 59 (2018): 58-64.
  21. LAKSHMINRUSIMHA S., et al. “Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide”. Seminar on Perinatology 40 (2016) 160-173. 
  22. PUTHIYACHIRAKKAL M and MHANNA MJ. “Pathophysiology, management, and outcome of persistent pulmonary hypertension of the newborn: a clinical review”. Frontiers in Pediatrics 1 (2013): 23.
  23. WALSH-SUKYS MC., et al. “Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes”. Pediatrics 105 (2000): 14-20.
  24. WUNG JT., et al. “Management of infants with severe respiratory failure and persistence of the fetal circulation, without hyperventilation”. Pediatrics 76 (1985): 488-494.
  25. ANGELES DM. “Pathophysiology and nursing management of persistent pulmonary hypertension of the newborn”. MCN: The American Journal of Maternal/Child Nursing 17 (1992) 314-321.
×

Citation

Citation: Virender Verma., et al. “Evidence Based Practice towards Pharmacological Management of Persistent Pulmonary Hypertension of Newborn in Neonatal Intensive Care Unit”.Acta Scientific Pharmacology 1.1 (2020): 20-24.




Member In



News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for March Issue
    The last date for submission of articles for regular Issues is February 29, 2020.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US